PWM
UTHR icon

Parkworth Wealth Management’s United Therapeutics UTHR Stock Holding History

Parkworth Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$575 Hold
2
– – ﹤0.01% 602
2025
Q1 		$617 Hold
2
– – ﹤0.01% 364
2024
Q4 		$706 Buy
+2
New +$735 ﹤0.01% 347

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Parkworth Wealth Management's UTHR Position: Q2 2025 in Review

Parkworth Wealth Management held its United Therapeutics (UTHR) position steady in Q2 2025 at 2 shares worth $575. The position accounts for ﹤0.01% of the portfolio, ranked #602.

Parkworth Wealth Management first reported a position in UTHR in Q4 2024 and has held it in 3 quarters since. The position peaked at $706 in Q4 2024. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of United Therapeutics worth $575 as of Q2 2025.
  • Parkworth Wealth Management left its United Therapeutics share count unchanged in Q2 2025.
  • United Therapeutics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #602 holding.
  • Parkworth Wealth Management first reported a position in United Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's United Therapeutics position peaked at $706 in Q4 2024.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.